TY - CHAP
T1 - Cancer Imaging in Immunotherapy
AU - Ayoub, Mira
AU - Eleneen, Yousra
AU - Colen, Rivka R.
N1 - Publisher Copyright:
© 2020, Springer Nature Switzerland AG.
PY - 2020
Y1 - 2020
N2 - Immune therapeutics are revolutionizing cancer treatments. In tandem, new and confounding imaging characteristics have appeared that are distinct from those typically seen with conventional cytotoxic therapies. In fact, only 10% of patients on immunotherapy may show tumor shrinkage, typical of positive responses on conventional therapy. Conversely, those on immune therapies may initially demonstrate a delayed response, transient enlargement followed by tumor shrinkage, stable size, or the appearance of new lesions. New imaging response criteria, such as the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) and immune-related Response Criteria (irRC), are being implemented in many trials. However, FDA approval of emerging therapies, including immunotherapies, still relies on the current RECIST criteria. In this chapter, we review the traditional and new imaging response criteria for evaluation of solid tumors and briefly touch on some of the more commonly associated immunotherapy-induced adverse events.
AB - Immune therapeutics are revolutionizing cancer treatments. In tandem, new and confounding imaging characteristics have appeared that are distinct from those typically seen with conventional cytotoxic therapies. In fact, only 10% of patients on immunotherapy may show tumor shrinkage, typical of positive responses on conventional therapy. Conversely, those on immune therapies may initially demonstrate a delayed response, transient enlargement followed by tumor shrinkage, stable size, or the appearance of new lesions. New imaging response criteria, such as the immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) and immune-related Response Criteria (irRC), are being implemented in many trials. However, FDA approval of emerging therapies, including immunotherapies, still relies on the current RECIST criteria. In this chapter, we review the traditional and new imaging response criteria for evaluation of solid tumors and briefly touch on some of the more commonly associated immunotherapy-induced adverse events.
KW - Cancer imaging
KW - Immune imaging criteria
KW - Immunotherapy
KW - irRC
KW - irRECIST
UR - http://www.scopus.com/inward/record.url?scp=85083631880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083631880&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-41008-7_18
DO - 10.1007/978-3-030-41008-7_18
M3 - Chapter
C2 - 32301025
AN - SCOPUS:85083631880
T3 - Advances in Experimental Medicine and Biology
SP - 309
EP - 324
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -